EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Antiretroviral Pregnancy Registry : Three decades of prospective monitoring for birth defects

Jessica D Albano, Angela E Scheuerle, D Heather Watts, Karen P Beckerman, Lynne M Mofenson, Andreas Pikis, Vani Vannappagari, Daniel Seekins, Taylor S Cook, Hugh Tilson, Antiretroviral Pregnancy Registry Steering Committee

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.5801 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Jessica D Albano und 10 weiteren Autor:innen. Beteiligte Einrichtung: Real World & Late Phase, Syneos Health, Morrisville, North Carolina, USA. Hauptthemen laut MEDLINE: Registries, Abnormalities, Drug-Induced, Pregnancy Complications, Infectious, HIV Infections. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Antiretroviral Pregnancy Registry.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Antiretrovirals (ARVs) are life‐saving drugs used for the treatment and prevention of HIV infection and antiviral drugs (AVs) for the treatment of chronic HBV infection. ARVs have proven highly effective in reducing perinatal HIV transmission, however the risk of birth defects from prenatal exposure to ARVs/AVs is an ongoing concern. The Antiretroviral Pregnancy Registry (APR), an international, prospective exposure‐registration cohort study, monitors ARV and AV use in pregnancy for early signals of teratogenicity. This communication reports results of 30‐years' experience of ARV/AV exposure during pregnancy and lessons learned through continuous quality improvement. Methods and Results Birth defect prevalence is estimated and compared to internal and external groups. Statistical inference is based on exact methods for binomial proportions. Between 2006 and 2023, cumulative enrollment more than tripled from 6893 to 25 960 pregnancies and ARVs/AVs monitored increased from 29 to 222. Through January 2023, there were 21 636 live births and 631 outcomes with birth defects, for overall prevalence of 2.9/100 live births (95% CI 2.7, 3.2). The birth defect prevalence was 3.0% (95% CI 2.7%, 3.3%) among first trimester exposures and 2.8% (95% CI 2.5%, 3.2%) among second/third trimester exposures (prevalence ratio 1.04 [95% CI 0.89, 1.21]).

Conclusions

Birth defect prevalence is not statistically significantly different between first trimester ARV/AV pregnancy exposures compared to second/third trimester exposures and is also not different from two population‐based surveillance systems: 2.72/100 live births reported in the Metropolitan Atlanta Congenital Defects Program (MACDP); and 4.17/100 live births from the Texas Birth Defects Registry (TBDR).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RegistriesAbnormalities, Drug-InducedPregnancy Complications, InfectiousHIV InfectionsHumansPregnancyFemaleProspective StudiesAdultPrevalenceInfant, NewbornAnti-Retroviral AgentsAnti-HIV AgentsAntiviral AgentsYoung AdultCongenital AbnormalitiesCohort Studies

Stichwörter der Autor:innen

HIVPrEPantiretroviralbirth defectshepatitis Bpregnancy

Substanzen

Anti-Retroviral AgentsAnti-HIV AgentsAntiviral Agents

Autor:innen und Institutionen

  • Real World & Late Phase, Syneos Health, Morrisville, North Carolina, USA.
  • Department of Pediatrics, Division of Genetics and Metabolism, University of Texas Southwestern, Dallas, Texas, USA.
  • Formerly of Office of the Global AIDS Coordinator and Health Diplomacy, U.S. Department of State, Washington, District of Columbia, USA.
  • Maternal Fetal Medicine, Zucker School of Medicine at Hofstra University, Staten Island University Hospital, Staten Island, New York, USA.
  • Senior HIV Technical Advisor, Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia, USA.
  • Division of Antivirals, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.

Förderung

  • Antiretroviral Pregnancy Registry

Zitieren

APA

Albano, J. D., Scheuerle, A. E., Watts, D. H., Beckerman, K. P., Mofenson, L. M., Pikis, A., Vannappagari, V., Seekins, D., Cook, T. S., Tilson, H., & Antiretroviral Pregnancy Registry Steering Committee (2024). The Antiretroviral Pregnancy Registry : Three decades of prospective monitoring for birth defects. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5801

Vancouver

Albano JD, Scheuerle AE, Watts DH, Beckerman KP, Mofenson LM, Pikis A, et al. The Antiretroviral Pregnancy Registry : Three decades of prospective monitoring for birth defects. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5801

BibTeX
@article{Albano2024,
  author = {Albano, Jessica D and Scheuerle, Angela E and Watts, D Heather and Beckerman, Karen P and Mofenson, Lynne M and Pikis, Andreas and Vannappagari, Vani and Seekins, Daniel and Cook, Taylor S and Tilson, Hugh and Antiretroviral Pregnancy Registry Steering Committee, Antiretroviral Pregnancy Registry Steering Committee},
  title = {The Antiretroviral Pregnancy Registry : Three decades of prospective monitoring for birth defects},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.5801}
}
Kostenlos starten →